Recombinant protein vaccines, a proven approach against coronavirus pandemics
With the COVID-19 pandemic now ongoing for close to a year, people all over the world are
still waiting for a vaccine to become available. The initial focus of accelerated global …
still waiting for a vaccine to become available. The initial focus of accelerated global …
Scientific rationale for developing potent RBD-based vaccines targeting COVID-19
H Kleanthous, JM Silverman, KW Makar, IK Yoon… - npj Vaccines, 2021 - nature.com
Vaccination of the global population against COVID-19 is a great scientific, logistical, and
moral challenge. Despite the rapid development and authorization of several full-length …
moral challenge. Despite the rapid development and authorization of several full-length …
Whole inactivated virus and protein-based COVID-19 vaccines
PJ Hotez, ME Bottazzi - Annual Review of Medicine, 2022 - annualreviews.org
The rapid development and deployment of mRNA and adenovirus-vectored vaccines
against coronavirus disease 2019 (COVID-19) continue to astound the global scientific …
against coronavirus disease 2019 (COVID-19) continue to astound the global scientific …
An aluminum hydroxide: CpG adjuvant enhances protection elicited by a SARS-CoV-2 receptor binding domain vaccine in aged mice
E Nanishi, F Borriello, TR O'Meara… - Science translational …, 2021 - science.org
Global deployment of vaccines that can provide protection across several age groups is still
urgently needed to end the COVID-19 pandemic, especially in low-and middle-income …
urgently needed to end the COVID-19 pandemic, especially in low-and middle-income …
[HTML][HTML] Evaluation of safety and immunogenicity of receptor-binding domain-based COVID-19 vaccine (Corbevax) to select the optimum formulation in open-label …
S Thuluva, V Paradkar, SR Gunneri, V Yerroju… - …, 2022 - thelancet.com
Background We assessed the efficacy of a receptor-binding domain (RBD)-based protein
subunit COVID-19 vaccine. Methods A randomised Phase-1/2 trial followed by a Phase-2 …
subunit COVID-19 vaccine. Methods A randomised Phase-1/2 trial followed by a Phase-2 …
[HTML][HTML] Efficacy of mRNA, adenoviral vector, and perfusion protein COVID-19 vaccines
MR Zinatizadeh, PK Zarandi, M Zinatizadeh… - Biomedicine & …, 2022 - Elsevier
Abstract Coronavirus disease 2019 (COVID-19) has a devastating impact on global
populations triggered by a highly infectious viral sickness, produced by the severe acute …
populations triggered by a highly infectious viral sickness, produced by the severe acute …
Molecular aspects concerning the use of the SARS-CoV-2 receptor binding domain as a target for preventive vaccines
Y Valdes-Balbin, D Santana-Mederos… - ACS central …, 2021 - ACS Publications
The development of recombinant COVID-19 vaccines has resulted from scientific progress
made at an unprecedented speed during 2020. The recombinant spike glycoprotein …
made at an unprecedented speed during 2020. The recombinant spike glycoprotein …
Recombinant vaccines in 2022: a perspective from the cell factory
MT de Pinho Favaro, J Atienza-Garriga… - Microbial cell …, 2022 - Springer
The last big outbreaks of Ebola fever in Africa, the thousands of avian influenza outbreaks
across Europe, Asia, North America and Africa, the emergence of monkeypox virus in …
across Europe, Asia, North America and Africa, the emergence of monkeypox virus in …
[HTML][HTML] An engineered SARS-CoV-2 receptor-binding domain produced in Pichia pastoris as a candidate vaccine antigen
M Limonta-Fernández, G Chinea-Santiago… - New …, 2022 - Elsevier
Developing affordable and easily manufactured SARS-CoV-2 vaccines will be essential to
achieve worldwide vaccine coverage and long-term control of the COVID-19 pandemic …
achieve worldwide vaccine coverage and long-term control of the COVID-19 pandemic …
Genetic modification to design a stable yeast-expressed recombinant SARS-CoV-2 receptor binding domain as a COVID-19 vaccine candidate
Abstract Background Coronavirus disease 2019 (COVID-19) caused by SARS-CoV-2 has
now spread worldwide to infect over 110 million people, with approximately 2.5 million …
now spread worldwide to infect over 110 million people, with approximately 2.5 million …